AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback